• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.

作者信息

Dowell Jonathan E, Minna John D

机构信息

University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA.

出版信息

Nat Clin Pract Oncol. 2006 Apr;3(4):170-1. doi: 10.1038/ncponc0476.

DOI:10.1038/ncponc0476
PMID:16596125
Abstract
摘要

相似文献

1
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.表皮生长因子受体（EGFR）突变与分子靶向治疗：肺癌治疗的新时代。
Nat Clin Pract Oncol. 2006 Apr;3(4):170-1. doi: 10.1038/ncponc0476.
2
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.非小细胞肺癌中表皮生长因子受体基因突变：吉非替尼和厄洛替尼治疗之外的影响。
Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16.
3
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.表皮生长因子受体基因组扩增在预测非小细胞肺癌对激酶抑制剂临床反应中的相关性。
Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.
4
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.表皮生长因子受体突变、小分子激酶抑制剂与非小细胞肺癌：当前认知与未来方向
J Clin Oncol. 2005 Apr 10;23(11):2556-68. doi: 10.1200/JCO.2005.07.799. Epub 2005 Mar 14.
5
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.晚期非小细胞肺癌中的表皮生长因子受体突变与酪氨酸激酶抑制剂治疗
Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5.
6
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?哪种生物标志物能预测肺癌患者从EGFR-TKI治疗中获益？
Br J Cancer. 2007 Mar 26;96(6):857-63. doi: 10.1038/sj.bjc.6603665. Epub 2007 Feb 27.
7
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].[表皮生长因子受体突变与非小细胞肺癌的靶向治疗]
Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6.
8
Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.利用表皮生长因子受体（EGFR）状态实现个性化治疗：肺癌研究人员取得了一项里程碑式成果。
J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28.
9
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.预测接受表皮生长因子酪氨酸激酶抑制剂治疗的非小细胞肺癌患者的临床获益情况。
Cold Spring Harb Symp Quant Biol. 2005;70:483-8. doi: 10.1101/sqb.2005.70.048.
10
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.表皮生长因子受体（EGFR）基因拷贝数增加与非小细胞肺癌中的EGFR突变及腺癌密切相关：一项对182例患者的显色原位杂交研究。
Lung Cancer. 2008 Sep;61(3):328-39. doi: 10.1016/j.lungcan.2008.01.009. Epub 2008 Mar 4.

引用本文的文献

1
Two decades of advances in clinical oncology - lessons learned and future directions.临床肿瘤学二十年进展——经验教训与未来方向
Nat Rev Clin Oncol. 2024 Nov;21(11):771-780. doi: 10.1038/s41571-024-00945-4. Epub 2024 Oct 1.
2
The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer.泛素系统：在非小细胞肺癌中调控细胞信号。
Cell Mol Biol Lett. 2020 Jan 16;25:1. doi: 10.1186/s11658-019-0193-6. eCollection 2020.
3
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
TNF 驱动的适应性反应介导肺癌对 EGFR 抑制的耐药性。
J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148. Epub 2018 May 7.
4
Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.组织学分级可预测转移性肺腺癌中表皮生长因子受体突变的发生率。
Med Sci (Basel). 2017 Dec 11;5(4):34. doi: 10.3390/medsci5040034.
5
Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.由于维生素D信号上调，p53基因的基因突变与miR-17∼92簇的抑制在非小细胞肺癌中具有合成致死作用。
Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17.
6
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.表皮生长因子受体在脑胶质瘤中的作用：信号转导、神经病理学、影像学和放射抵抗。
Neoplasia. 2010 Sep;12(9):675-84. doi: 10.1593/neo.10688.
7
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.鉴定新型激酶靶点用于治疗雌激素受体阴性乳腺癌。
Clin Cancer Res. 2009 Oct 15;15(20):6327-40. doi: 10.1158/1078-0432.CCR-09-1107. Epub 2009 Oct 6.
8
Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.唾液腺型肺癌：一项表皮生长因子受体免疫组织化学、分子遗传学及突变分析研究
Mod Pathol. 2008 Sep;21(9):1168-75. doi: 10.1038/modpathol.2008.113. Epub 2008 Jun 27.